



# Geriatric Care and Counseling

**Asst. Prof. Titima Wongviriyawong, MD**

*Division of Geriatric Medicine, Department of Medicine,  
Faculty of Medicine Siriraj Hospital*

23 November 2024

# Global Situation



	ประชากรอายุ 60 ปีขึ้นไป	ประชากรอายุ 65 ปีขึ้นไป
“สังคมสูงอายุ” (Aged society)	มากกว่าร้อยละ 10	มากกว่าร้อยละ 7
“สังคมสูงอายุอย่างสมบูรณ์” (Complete-aged society)	มากกว่าร้อยละ 20 พ.ศ. 2565 (ค.ศ. 2022)	มากกว่าร้อยละ 14
“สังคมสูงอายุระดับสุดยอด” (Super-aged society)	มากกว่าร้อยละ 28	มากกว่าร้อยละ 20

2044 Global complete-aged society

Age > 60 = 21.2%

Age > 65 = 14.2%

Mahidol population gazette 2024

# THE SILVER TSUNAMI

IMPACT  
*Flight, Freeze, or Fight?*





Photo Credit: Graham Mackay

# Comprehensive Geriatric Assessment



## Physical

- Acute illness
- Comorbid diseases
- Medication reconciliation
- Nutritional status
- Substance/alcohol




## Mental

- Delirium
- Dementia
- Depression



## Functional

- BADLs
- IADLs
- Decision-making capacity



## Social

- Caregiver
- Financial status
- Home environment
- Healthcare service

# Geriatric Syndrome




- Intellectual impairment TMSE, MOCA, MMSE-Thai 2002, RUDAS, etc.
- Incontinence Fecal incontinence, urinary incontinence
- Immobility Deconditioning after 1 week immobilization
- Instability Falling > 2 episodes/ 1 yr → significant
- Inanition Malnutrition, eating problem
- Iatrogenesis \*\*Medication problem\*\*
- Frailty
- Sarcopenia

A word cloud featuring the word 'FRAILTY' in the largest, bold, blue font in the center. Surrounding it are the words 'MORTALITY' and 'SARCOPENIA' in various sizes and colors, including blue, green, yellow, and orange. The words are arranged in a circular pattern, with 'FRAILTY' being the most prominent. The background is white with a blue and green curved border at the bottom.

# "Multidimensional geriatric syndrome"

**INDEPENDENT** An independent risk factor for mortality



# FRAIL

OLDER PERSON

A state of increased vulnerability to poor resolution of homeostasis after a stressor event which increases the risk of adverse clinical outcomes

**DEPENDENT**

Clegg A, et al. Lancet. 2013 Mar 2;381(9868):752-62  
Hoogendijk EO, et al. Lancet. 2019 Oct 12;394(10206):1365-1375  
Dent E, et al. Lancet. 2019 Oct 12;394(10206):1376-1386





# Diagnosis of Frailty

- Frailty Phenotype
- Frailty Index
- Clinical Frailty Scale
- FRAIL questionnaire



# Thai frailty index

30 items for frailty assessment

0-3 items = fit

4-7 items = prefrail

≥ 8 items = frail

Deficits accumulation 30 items

**Frailty: TFI > 0.25**

Frailty predicted mortality




Fig. 1. Deaths per 1000 person-years according to quartile of TFI score comparing between genders.

# Frailty Phenotype

## 1. Unintentional weight loss

- 4.5 or 5% of body weight in prior year

## 2. Weakness: grip strength

- Male BMI  $\leq 24 \text{ kg/m}^2$   $\leq 29 \text{ kg}$  Female BMI  $\leq 23 \text{ kg/m}^2$   $\leq 17 \text{ kg}$   
BMI 24.1-26  $\text{kg/m}^2$   $\leq 30 \text{ kg}$  BMI 23.1-26  $\text{kg/m}^2$   $\leq 17.3 \text{ kg}$   
BMI 26.1-28  $\text{kg/m}^2$   $\leq 30 \text{ kg}$  BMI 26.1-29  $\text{kg/m}^2$   $\leq 18 \text{ kg}$   
BMI  $> 28 \text{ kg/m}^2$   $\leq 32 \text{ kg}$  BMI  $> 29 \text{ kg/m}^2$   $\leq 21 \text{ kg}$

**0 = Robust**  
**1-2 = Pre-frail**  
 **$\geq 3$  = Frail**

## 3. Poor endurance and energy: self-report exhaustion

- Felt that everything I did was an effort in the last week
- Could not get going in the last week

0=1 day; 1=1-2 days; 2=3-4 days; 4= more than 4 days. Score  $\geq 2$  consider exhaustion

## 4. Slowness: time to walk 15 feet (4.57 m)

- Male height  $\leq 173 \text{ cm.}$   $\geq 7 \text{ sec;}$   $> 173 \text{ cm}$   $\geq 6 \text{ sec}$
- Female height  $\leq 159 \text{ cm.}$   $\geq 7 \text{ sec;}$   $> 159 \text{ cm}$   $\geq 6 \text{ sec}$

## 5. Low physical activity level: Minnesota Leisure Time Activity Questionnaire

- Male  $< 383 \text{ kCal/week}$  Female  $< 270 \text{ kCal/week}$



# FRAIL Questionnaire Screening Tool

**F**atigue

**R**esistance

**A**erobic

**I**llness

**L**oss of weight

**0 = Robust**

**1-2 = Pre-frail**


**≥ 3 = Frail**



# แบบสอบถามภาวะเปราะบางอย่างง่าย ฉบับภาษาไทย

คำถาม	คะแนน = 0	คะแนน = 1
1. ในช่วง 4 สัปดาห์ที่ผ่านมา ท่านรู้สึกอ่อนเพลียบ่อยมากแค่ไหน 1 = ตลอดเวลา, 2 = เกือบตลอดเวลา, 3 = บางเวลา, 4 = ส่วนน้อย, 5 = ไม่เคยเลย	<input type="checkbox"/> บางเวลา หรือ ส่วนน้อย หรือ ไม่เคยเลย	<input type="checkbox"/> ตลอดเวลา หรือ เกือบตลอดเวลา
2. เวลาท่านเดินขึ้นบันได 10 ขั้นด้วยตัวเองโดยไม่หยุดพัก และไม่ใช้อุปกรณ์ช่วย ท่านมีปัญหาหรือไม่	<input type="checkbox"/> ไม่มี	<input type="checkbox"/> มี
3. เวลาท่านเดินหลายร้อยเมตรด้วยตัวเองโดยไม่หยุดพัก และไม่ใช้อุปกรณ์ช่วย ท่านมีปัญหาหรือไม่	<input type="checkbox"/> ไม่มี	<input type="checkbox"/> มี
4. แพทย์เคยแจ้งว่าท่านมีโรคต่าง ๆ เหล่านี้หรือไม่ ได้แก่ <ul style="list-style-type: none"> <li><input type="checkbox"/> โรคความดันโลหิตสูง</li> <li><input type="checkbox"/> โรคเบาหวาน</li> <li><input type="checkbox"/> โรคมะเร็ง (ไม่รวมมะเร็งผิวหนัง)</li> <li><input type="checkbox"/> โรคปอดเรื้อรัง</li> <li><input type="checkbox"/> โรคหลอดเลือดหัวใจกำเริบ</li> <li><input type="checkbox"/> ภาวะหัวใจวาย</li> <li><input type="checkbox"/> อาการแน่นหน้าอกจากโรคหลอดเลือดหัวใจ</li> <li><input type="checkbox"/> โรคหอบหืด</li> <li><input type="checkbox"/> ภาวะข้ออักเสบ</li> <li><input type="checkbox"/> โรคหลอดเลือดสมอง</li> <li><input type="checkbox"/> โรคไต</li> </ul>	<div>1-2 = Pre-frail</div> <div>≥ 3 = Frail</div> <input type="checkbox"/> 0-4 โรค	<input type="checkbox"/> 5-11 โรค
5. ปัจจุบันท่านหนักเท่าไรตอนที่ถอดรองเท้า = ..... กิโลกรัม 1 ปีก่อนหน้านี้ ท่านหนักเท่าไรตอนที่ถอดรองเท้า = ..... กิโลกรัม	<input type="checkbox"/> น้ำหนัก ลดน้อยกว่า 5%	<input type="checkbox"/> น้ำหนัก ลดมากกว่าหรือเท่ากับ 5%

# Frailty and Sarcopenia Relationship



# Diagnosis of Sarcopenia: AWGS 2019

1. Low appendicular skeletal muscle mass (ASM)
2. Low muscle strength
3. Low physical performance

**Sarcopenia = 1 + (2 or 3)**

**Severe sarcopenia = 1 + 2 + 3**



## Primary health care or community preventive services settings

### Case Finding

- Calf circumference (M: <34 cm, F: <33 cm)
- or** ➤ SARC-F ≥4
- or** ➤ SARC-CalF ≥11

### Assessment

#### Muscle strength

- Handgrip strength (M: <28 kg, F: <18 kg)

#### Physical performance

- 5-time chair stand test (≥12 s)

**“Possible sarcopenia”**

**Lifestyle modifications in diet and exercise**

Refer to confirm diagnosis

### Diagnosis

## Acute to chronic health care or clinical research settings

### Case Finding

Presence of any of the following clinical conditions:

- Functional decline or limitation; unintentional weight loss; depressive mood; cognitive impairment; repeated falls; malnutrition
- Chronic conditions (heart failure, chronic obstructive pulmonary disease, diabetes mellitus, chronic kidney disease, etc)

If no clinical conditions above are present:

- Calf circumference (M: <34 cm, F: <33 cm)
- or** ➤ SARC-F ≥4
- or** ➤ SARC-CalF ≥11

#### Muscle strength

- Handgrip strength (M: <28 kg, F: <18 kg)

#### Physical performance

- 6-metre walk: <1.0 m/s
- or** ➤ 5-time chair stand test: ≥12 s
- or** ➤ Short Physical Performance Battery: ≤9

#### Appendicular skeletal muscle mass (ASM)

- Dual-energy X-ray absorptiometry (M: <7.0 kg/m<sup>2</sup>, F: <5.4 kg/m<sup>2</sup>)
- or** ➤ Bioelectrical impedance analysis (M: <7.0 kg/m<sup>2</sup>, F: <5.7 kg/m<sup>2</sup>)

### Sarcopenia

Low ASM + low muscle strength  
**OR** Low physical performance

### Severe sarcopenia

Low ASM + low muscle strength  
**AND** Low physical performance

**Fig. 1.** AWGS 2019 algorithm for sarcopenia. F, female; M, male.




# Prevention of Frailty and Sarcopenia

1. Resistance exercise and aerobic exercise
2. Adequate caloric and protein intake  
**protein 1.0 – 1.2 g/kg/day**
3. Lifestyle modification
  - Alcohol cessation
  - Smoking cessation
4. Avoid unnecessary medications



# The effectiveness of **intermediate care including transitional care interventions** on **FUNCTION**, healthcare utilization and costs



Co-ordinate care

Enhance  
communication

Set goals of care

Systematic follow up

1. Monitoring frailty screening process and collaborate with existing teams
2. Provide appropriate care model & discharge destinations
  - IMC ( subacute / post-acute ward )
  - home with service & nursing home



3. Monitor and facilitate transitional process through multidisciplinary team
4. Continuing cooperation with discharge destinies & provide consultation to reduce readmission



Acute care



Transitional care



Intermediate care

Community care



# ศูนย์บริการสุขภาพผู้สูงอายุศิริราช-สมุทรสาคร





# Dietary Recommendation

# Recommended Diet for Older Adults

Population	Calories (kCal/kg/day)	Protein (g/kg/day)	ONS	Note
General elderly	30 – 35	1.0 – 1.2	N/A	Micronutrients, fiber Age > 75; avoid diet restriction
High risk elderly: frail, malnutrition, institutionalized, etc.		1.2 – 1.5	✓ 400 kCal/day (Prot. > 30 g/d) ≥ 1 month	Environment, finger food, avoid diet restriction
Polymorbid internal medicine patients	27 – 30	> 1	✓ if needed within 48 hr → after discharge	Prefer oral feeding
Hip fracture			✓ reduce postoperative complications	
Dementia	Food preference (Ad lib)		✓	Avoid diet restriction Avoid systemic appetite stimulant

Water: women 1.6 L, men 2.0 L


Volkert D, et al. *Clin Nutr.* 2022 Apr;41(4):958-989.

Gomes F, et al. *Clin Nutr.* 2018;37(1):336-53.

Deutz NE, et al. *Clin Nutr.* 2014;33(6):929-36.

AGS 2013

# Synergistic Effect: protein and exercise



X



**Meat (white), dairy product 50%**  
**Plant 50%**



**1000 mg**  
**800 IU**

**elemental calcium**  
**vitamin D3**



# Sources of calcium

Main intake from food



Dairy  
~300 mg/serving



Diet  
~200 mg/day



Supplements  
e.g.  $\text{CaCO}_3$   
(40% elemental Ca)

Should not exceed 1,500  
mg/day

# Tube Feeding: when to employ?

## Older persons with reasonable prognosis

- If oral intake is expected to be impossible for more than 3 days
- Total caloric intake is expected to be <50% for more than 7 days
- Aware of refeeding syndrome in malnourished patients in the first 3 days of feeding
- Avoid restraining patients (either by physical or medical) to achieve tube feeding
- Oral feeding is still important even when fed by tube
- NG or PEG – does not prevent aspiration\*
  - Duration < 4 weeks: prefer NG tube
  - Duration > 4 weeks: prefer PEG
- Reconsider the benefit of tube feeding when prognosis is changed




# Delirium



# Delirium

- Underdiagnosed leads to morbidity and mortality
- Gold standard for diagnosis
  - DSM-5 criteria
- Screening tools
  - CAM
  - CAM-ICU
  - 3D-CAM
  - 4AT
  - NuDESC
  - Etc.



# DSM-5

- A. A disturbance in **attention** and **awareness** (reduced orientation to the environment)
- B. The disturbance **develops over a short period of time**, represents a **change from baseline attention and awareness**, and tends to **fluctuate** in severity during the course of a day
- C. An additional disturbance in cognition**
- D. The disturbances in Criteria A and C are **not better explained by another preexisting, established, or evolving neurocognitive disorder** and do not occur in the context of a severely reduced level of arousal, such as **coma**
- E. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a direct physiological consequence of another medical condition, substance intoxication or withdrawal, or exposure to a toxin, or is due to multiple etiologies



# CAM (Confusion Assessment Method)

1. Acute onset and fluctuating course
2. Inattention
3. Disorganized thinking
4. Altered level of consciousness

**1+2+(3 or 4)**

# Treatment of Delirium

- Non-pharmacologic treatment

**Mainstay therapy**

- Pharmacologic treatment

**Harm to**

- Patient
- Treatment
- Medical personnel

**Antipsychotics increase mortality  
esp. in dementia**

- **Correct the cause!**
- **Delirium prevention**

## Drugs

- Haloperidol (1<sup>st</sup> line); avoid IV route due to QT prolongation
- Risperidone
- Quetiapine
- Olanzapine
- Trazodone
- Lorazepam (withdrawal)

## Drugs for prevention

- **NONE**





# Delirium Prevention Mnemonic

## SMARD

**S**leep hygiene

**M**obility

**A**ids and appliances

**R**eorientation

**D**ehydration (avoid), **D**iet



# Multicomponent Non-pharmacologic Interventions

Approach	Description
Orientation and therapeutic activities	Provide lighting, signs, calendars, clocks Reorient the patient to time, place, person, your role Introduce cognitively stimulating activities (eg, reminiscing) Facilitate regular visits from family, friends
Fluid repletion	Encourage patients to drink; consider parenteral fluids if necessary Seek advice regarding fluid balance in patients with comorbidities (heart failure, renal disease)
Early mobilization	Encourage early postoperative mobilization, regular ambulation Keep walking aids (canes, walkers) nearby at all times Encourage all patients to engage in active, range-of-motion exercises
Feeding assistance	Follow general nutrition guidelines and seek advice from dietician as needed Ensure proper fit of dentures
Vision and hearing	Resolve reversible cause of the impairment Ensure working hearing and visual aids are available and used by patients who need them

# Multicomponent Non-pharmacologic Interventions

Approach	Description
Sleep enhancement	Unit-wide noise-reduction strategies (e.g., silent pill crushers, vibrating beepers, and quiet hallways) Avoid medical or nursing procedures during sleep if possible Schedule medications to avoid disturbing sleep Reduce noise at night
Infection prevention	Look for and treat infections Avoid unnecessary catheterization Implement infection-control procedures
Pain management	Assess for pain, especially in patients with communication difficulties Begin and monitor pain management in patients with known or suspected pain
Hypoxia protocol	Assess for hypoxia and oxygen saturation
Psychoactive medication protocol	Review medication list for both types and number of medications

**Adherence is an important**

# Appropriate Drug Use

# Appropriate Drug Use in the Elderly

Older adults tend to have more drug adverse events

- Polypharmacy – drug-drug interaction, drug-disease interaction, drug duplication, prescribing cascade
- Multiple comorbidities
- Physiologic changes
  - Pharmacokinetics:
    - Reduced hepatic and renal clearance
    - Changes in Vd
  - Pharmacodynamics:
    - More sensitive to narcotics
    - Decrease baroreflex response

**Any new symptoms - drugs could be the cause!**





# AGS BEERS

CRITERIA® 2023





# Drugs with strong anticholinergic property

<b>Antihistamines</b> <ul style="list-style-type: none"> <li>- Brompheniramine</li> <li>- Chlorpheniramine</li> <li>- Cyproheptadine</li> <li>- Dimenhydrinate</li> <li>- Diphenhydramine</li> <li>- Hydroxyzine</li> <li>- Triprolidine</li> </ul>	<b>Antimuscarinics</b> <ul style="list-style-type: none"> <li>- Darifenacin</li> <li>- Fesoterodine</li> <li>- Flavoxate</li> <li>- Oxybutynin</li> <li>- Solifenacin</li> <li>- Tolterodine</li> <li>- Trosipium</li> </ul>	<b>Antispasmodics</b> <ul style="list-style-type: none"> <li>- Belladonna alkaloids</li> <li>- Clidinium/ chlordiazepoxide</li> <li>- Dicyclomine</li> <li>- Scopolamine</li> </ul>	<b>Antiemetic</b> <ul style="list-style-type: none"> <li>- Prochlorperazine</li> <li>- Promethazine</li> </ul>
<b>Antidepressants</b> <ul style="list-style-type: none"> <li>- Amitriptyline</li> <li>- Amoxapine</li> <li>- Clomipramine</li> <li>- Desipramine</li> <li>- Doxepin (&gt;6 mg)</li> <li>- Imipramine</li> <li>- Nortriptyline</li> <li>- Paroxetine</li> </ul>	<b>Antipsychotics</b> <ul style="list-style-type: none"> <li>- Chlorpromazine</li> <li>- Clozapine</li> <li>- Loxapine</li> <li>- Olanzapine</li> <li>- Perphenazine</li> <li>- Thioridazine</li> <li>- Trifluoperazine</li> </ul>	<b>Skeletal muscle relaxants</b> <ul style="list-style-type: none"> <li>- Orphenadrine</li> </ul>	<b>Antiparkinsonian drugs</b> <ul style="list-style-type: none"> <li>- Benztropine</li> <li>- Trihexyphenidyl</li> </ul>



# Drugs to avoid

Drugs	Rationale	Alternative
CVS		
Doxazosin Prazosin Clonidine Methyldopa Reserpine (>0.1 mg/day)	Avoid as 1 <sup>st</sup> line treatment of hypertension; Orthostatic hypotension	Thiazide diuretics, ACEI, ARB, long-acting dihydropyridine CCB
Digoxin	Avoid as 1 <sup>st</sup> line treatment for heart failure. If used for AF or heart failure, avoid dosages >0.125 mg/day	
Nifedipine, immediate release	Orthostatic hypotension	Thiazide diuretics, ACEI, ARB, long-acting dihydropyridine CCB
Amiodarone	Avoid as 1 <sup>st</sup> line treatment for AF unless patient has heart failure or substantial LVH (favor rhythm control than rate control)	

# Drugs to avoid (2023)

Drugs	Rationale	Alternative
CVS		
<b>Rivaroxaban</b> for long-term treatment of nonvalvular atrial fibrillation or VTE	Avoid as rx as long-term for VTE/non-valvular AF: higher bleeding than other DOACs (esp. apixaban)	
<b>Warfarin</b> for treatment of nonvalvular atrial fibrillation or VTE	Compared with DOACs, warfarin has higher risks of major bleeding (particularly intracranial bleeding) and similar or lower effectiveness for treatment of nonvalvular atrial fibrillation and VTE. DOACs are thus the preferred choice for anticoagulation for most people with these conditions	Note: For older adults who have been using warfarin long-term, it may be reasonable to continue this medication, particularly among those with well-controlled INRs (>70% time in the therapeutic range) and no ADR
<b>Aspirin</b> for primary prevention of cardiovascular disease	Risk of major bleeding from aspirin increases markedly in older age. There is less evidence about stopping aspirin among long-term users, although similar principles as for initiation may apply.	Note: Aspirin is generally indicated for secondary prevention in older adults with established cardiovascular disease

# Drugs to avoid

Drugs	Rationale	Alternative
CNS		
<b>Antidepressants</b> <ul style="list-style-type: none"> <li>• Amitriptyline</li> <li>• Doxepin &gt;6 mg/day</li> <li>• Imipramine</li> <li>• Nortriptyline</li> <li>• Paroxetine</li> </ul>	Highly anticholinergic, sedating, and cause orthostatic hypotension; safety profile of low-dose doxepin ( $\leq 6$ mg/day)	Sertraline, escitalopram, etc.
<b>Antipsychotics</b>	Increased risk of cerebrovascular accident and greater rate of cognitive decline and mortality in persons with dementia	Except in schizophrenia or bipolar disorder, or for short-term use as antiemetic during chemotherapy
Benzodiazepines Benzodiazepine receptor agonist hypnotics (Z-drugs)	Increase risk of cognitive impairment, delirium, falls, fractures, and motor vehicle crashes in older adults	May be appropriate for seizure disorders, REM sleep behavior disorder, benzodiazepine/alcohol withdrawal, ethanol withdrawal, severe GAD

# Drugs to avoid

Drugs	Rationale	Alternative
Gastrointestinal		
Metoclopramide	EPS in prolonged exposure elderly	Unless for gastroparesis with duration of use not to exceed 12 weeks except in rare cases
Mineral oil	Aspiration	
PPIs	<i>C.difficile</i> infection, bone loss and fractures	Avoid scheduled use for >8 weeks unless for high-risk patients

# Drugs to avoid

Drugs	Rationale	Alternative
Pain medication		
Meperidine	Delirium	Other strong opioids
Non-cyclooxygenase-selective NSAIDs, oral	GI bleeding, nephrotoxicity, increase BP Avoid chronic use, unless other alternatives are not effective and patient can take gastroprotective agent	
Indomethacin Ketorolac	GI bleeding Indomethacin – delirium*	
Skeletal muscle relaxants	Anticholinergic adverse effects, sedation, increased risk of fractures. Questionable efficacy	Other medication , topical agents, non-pharmacologic therapy

Drugs	Rationale	Alternative
Endocrine		
Androgens	Potential for cardiac problems. Contraindicated in CA prostate	
Estrogens (± progestins)	Avoid systemic estrogen : Carcinogenic potential (breast, endometrium)	Acceptable to use low-dose intravaginal estrogen for management of dyspareunia, recurrent lower UTI or other vaginal symptoms
Megestrol	Minimal effect on weight; increases risk of thrombotic events and possibly death	
SU, long acting <ul style="list-style-type: none"> <li>Chlorpropamide</li> <li>Glibenclamide</li> <li>Glimepiride</li> </ul>	Pro <div>2023 – all SUs except glipizide</div>	<div>SUs long-acting agents (e.g., glibenclamide, glimepiride) confer a higher risk of prolonged hypoglycemia than short-acting agents (e.g., glipizide).</div>
Insulin, sliding scale (without concurrent use of basal/long-acting insulin)	Higher risk of hypoglycemia	Use regimens that contain basal insulin or long-acting insulin

# Adverse drug events

<b>Fall</b>	<b>Sedatives, vasodilators, diuretics</b>
<b>Parkinsonism</b>	<b>Flunarizine, cinnarizine, antipsychotics, metoclopramide</b>
<b>Orthostatic hypotension</b>	<b>Diuretics, antihypertensive agents esp. <math>\alpha</math>-blockers, sympatholytic, nitrate, bromocriptine, narcotics, sedatives, sildenafil, tricyclic antidepressants (TCA)</b>
<b>Urinary incontinence</b>	<b>Diuretics, anticholinergics (overflow incontinence), alcohol, caffeine</b>
<b>Urinary retention</b>	<b>Anticholinergics, antidepressants, antipsychotics, sedatives, narcotics, <math>\alpha</math>-adrenergic agonists, <math>\beta</math>-adrenergic agonists, calcium-channel blockers</b>
<b>Depression</b>	<b>Propranolol, clonidine, hydralazine, reserpine, narcotics, digitalis</b>
<b>Delirium</b>	<b>Narcotics, anticholinergics, sedatives, anticonvulsants, antiarrhythmics, digitalis, methyldopa, <math>\beta</math>-blocker</b>
<b>Renal failure</b>	<b>NSAIDs, diuretics (volume depletion), aminoglycoside, amphotericin B, contrast media</b>



# ADA 2024

Patient Characteristics	Reasonable A1c goal	Fasting glucose	Blood pressure	Lipid
<b>Healthy</b> (few coexisting chronic illnesses, intact cognitive and functional status)	<7.0-7.5%	80-130 mg/dL	<130/80 mmHg	Statins unless contraindicated or not tolerated
<b>Complex / intermediate</b> (multiple coexisting chronic illnesses* or 2+ instrumental ADL impairments or mild-to-moderate cognitive impairment)	<8.0%	90-150 mg/dL	<130/80 mmHg	Statins unless contraindicated or not tolerated
<b>Very complex/poor health</b> (LTC or end stage chronic illnesses** or moderate-to-severe cognitive impairment or 2+ basic ADL impairments)	Avoid reliance on A1C; avoiding hypoglycemia & symptomatic hyperglycemia	100-180 mg/dL	<140/90 mmHg	Consider likelihood benefit of statins

\* **Coexisting chronic illnesses** are conditions serious enough to require medications or lifestyle management and may include arthritis, cancer, congestive heart failure, depression, emphysema, falls, hypertension, incontinence, stage 3 or worse chronic kidney disease, myocardial infarction, and stroke. “Multiple” means at least three, but many patients may have five or more.

\*\***The presence of a single end-stage chronic illness**, such as stage 3–4 congestive heart failure or oxygen-dependent lung disease, chronic kidney disease requiring dialysis, or uncontrolled metastatic cancer, may cause significant symptoms or impairment of functional status and significantly reduce life expectancy.

# Diabetes and Frailty: An Expert Consensus Statement on the Management of Older Adults with Type 2 Diabetes

Level of frailty	Target	De-escalate threshold
Healthy Pre-frail Mild frailty	<ul style="list-style-type: none"> <li>• HbA1c &lt;7.5%, but <math>\geq</math> 6%</li> <li>• FPG 90 – 130 mg/dL</li> <li>• BP &lt;140/90 mmHg</li> </ul>	<b>7.0%</b>
Moderate frailty	<ul style="list-style-type: none"> <li>• HbA1c &lt;8.0%</li> <li>• FPG 110–150 mg/dL</li> <li>• BP &lt;140/90 mmHg</li> </ul>	<b>7.5%</b>
Severe Frailty	<ul style="list-style-type: none"> <li>• HbA1c &lt;8.5%</li> <li>• FPG 125–180 mg/dL</li> <li>• BP &lt;150/90 mmHg</li> </ul>	<b>7.5%</b>






# Known modifiers of glycated hemoglobin values in older adults

Artificially <b>increases</b> HbA1c	Artificially <b>reduces</b> HbA1c
Iron deficiency	Bleeding conditions (e.g. peptic ulcer disease)
B12 deficiency	Hemolytic conditions (e.g. valvular cardiac disease)
Anemia of chronic disease	Haemoglobinopathies (thalassemia/sickle cell etc.)
Chronic opioid use	Chronic liver disease




## Healthy/pre-frail/mild frailty

Re-evaluate level of frailty annually and within 3 months of any intervention



## Moderately frail


Re-evaluate level of frailty annually and within 3 months of any intervention





## Severely frail

Re-evaluate level of frailty annually and within 3 months of any intervention



# Blood Pressure Control in Frail Elderly



- SBP
  - Increases with age
- DBP
  - Age 50 – 60 yr – DBP starts to decline or stable
- Orthostatic hypotension – common in very old population, frail elderly, CVD
- Target BP
  - Healthy (fit) elderly = SBP 130 – 135 mmHg
  - Frail elderly (mild) = SBP 140 mmHg
  - Very frail elderly = SBP 130 – 150 mmHg
- CCB and diuretics are the most potent antihypertensive drugs in older adults


**Wide pulse pressure**

**START LOW,  
GO SLOW,  
BUT GO !**





# Drug-induced Delirium



กลุ่มยา	ชื่อยา	Mechanism
ยาระบบหัวใจและหลอดเลือด	Beta-blockers (metoprolol, propranolol) Methyldopa Digitalis	ไม่ชัดเจน  พิษต่อระบบประสาทส่วนกลาง
<b>Antiarrhythmics</b>	disopyramide	ฤทธิ์ anticholinergic
ยารักษาโรคระบบทางเดินหายใจ	Theophylline, steroids (high dose)	กระตุ้นระบบประสาทส่วนกลาง
ยาโรคระบบทางเดินอาหาร	Scopolamine, H <sub>2</sub> -blockers	ฤทธิ์ anticholinergic
<b>Benzodiazepines</b>	Lorazepam, alprazolam, clonazepam, diazepam, clorazepate, chlordiazepoxide	กดการทำงานของระบบประสาทส่วนกลางกรณีได้ยาติดต่อกันเป็นเวลานานและหยุดกระทันหันอาจเกิดอาการขาดยา (withdrawal)
<b>Benzodiazepine receptor agonist</b>	Zolpidem	กดการทำงานของระบบประสาทส่วนกลาง
<b>First-generation antihistamines</b>	Diphenhydramine, chlorpheniramine, cyproheptadine, dimenhydrinate, hydroxyzine	ฤทธิ์ anticholinergic กดการทำงานของระบบประสาทส่วนกลาง
<b>Anticholinergics</b>	Trihexyphenidyl, benztropine, oxybutynin	ฤทธิ์ anticholinergic
แอลกอฮอล์		กดการทำงานของระบบประสาทส่วนกลางอาการขาดสุรา (withdrawal)

กลุ่มยา	ชื่อยา	Mechanism
ยากันชัก	Phenobarbital, phenytoin	CNS depression (even therapeutic level)
<b>Tricyclic antidepressants</b>	Amitriptyline, nortriptyline, imipramine, doxepin >6mg	Anticholinergic effect
<b>Antipsychotic drugs*</b>	Chlorpromazine, thioridazine	Anticholinergic effect
<b>Dopaminergic drugs</b>	selegiline, rasagiline, pergolide, pramipexole, bromocriptine, cabergoline, levodopa	Increase DA
ยาต้านจุลชีพ ( <b>antibiotics</b> )	Fluoroquinolones Macrolides (clarithromycin) Penicillins (piperacillin/tazobactam) Cephalosporins (cefepime, ceftazidime, cefuroxime, cefazolin) Carbapenems (ertapenem)	Neurotoxicity
ยาคลายกล้ามเนื้อ	Orphenadrine, tolperisone, chlorzoxazone	Strong anticholinergic effect
ยาแก้ปวดกลุ่ม <b>NSAIDs</b>	Indomethacin	Uncertain
ยาแก้ปวดกลุ่ม <b>opioid</b>	Meperidine (pethidine), tramadol	Anticholinergic effect CNS depression
<b>Non-opioid analgesics</b>	Nefopam	Anticholinergic –like effect Monoaminergic effects (increase DA and NE) CNS hyperstimulation

# Dementia



# Dementia

- Diagnosis
  - $\geq 1$  cognitive domain impairment
  - Functional disturbance
- Common dementia
  - Alzheimer's disease: memory, visuospatial
  - Vascular dementia: executive function
  - Dementia with Lewy bodies (Lewy body dementia): visuospatial
  - Frontotemporal lobar degeneration (FTLD or FTD – old name): behavioral problem
  - Parkinson disease with dementia: executive function/ visuospatial



# DSM-5: major NCD

- A. There is evidence of substantial cognitive decline from a previous level of performance in **one or more of the domains** listed below, based on the concerns of the individual, a knowledgeable informant, or the clinician; **and a decline in neurocognitive performance**, typically involving test performance in the range of two or more standard deviations below appropriate norms (i.e. below the third percentile) on formal testing or equivalent clinical evaluation.
- B. The cognitive deficits are sufficient to **interfere with independence** (i.e. requiring minimal assistance with instrumental activities of daily living).
- C. The cognitive deficits do not occur exclusively in the context of a delirium.
- D. The cognitive deficits are not primarily attributable to another mental disorder (for example major depressive disorder and schizophrenia).




# DSM-5 Cognitive Domains

- **Complex attention** - involves sustained attention, divided attention, selective attention and information processing speed
- **Executive ability** - involves planning, decision making, working memory, responding to feedback, error correction, overriding habits and mental flexibility
- **Learning and memory** - involves immediate memory, recent memory (free recall, cued recall and recognition memory) and long term memory
- **Language** - involves expressive language (naming, fluency, grammar and syntax) and receptive language
- **Perceptual - Motor - Visual perception, praxis**- involves picking up the telephone, handwriting, using a fork/spoon
- **Social cognition** - involves recognition of emotions and behavioural regulation, social appropriateness in terms of dress, grooming and topics of conversation



### แผนภูมิที่ 3 การวินิจฉัยแยกโรคในภาวะสมองเสื่อม







# Dementia


- Work up reversible cause
  - TSH, VDRL, B12
  - Organ failures
  - Mood problem esp. depression
- Neuroimaging of choice = MRI brain dementia protocol
- Treatment
  - Pharmacologic treatment
  - Non-pharmacologic treatment
- Cholinesterase inhibitors: Donepezil, rivastigmine, galantamine
- Memantine



# Alzheimer's disease




# Early onset AD




Precuneus  
atrophy

# Vascular dementia





# bvFTD





# PSP



# MSA



# Pharmacologic Treatment

	Alzheimer's disease			AD with CVD			Vascular dementia			Parkinson's disease with dementia			Dementia with Lewy Bodies			bvFTD			MCI
Donepezil																			
Rivastigmine																			
Rivastigmine patch																			
Galantamine																			
Memantine																			
Ginkgo biloba extract																			
Nicergoline																			



# ข้อควรระวัง

## Cholinesterase Inhibitors

- Side effect: anorexia, N/V, diarrhea, bradycardia, syncope
- Drugs to avoid
  - Anticholinergic drugs
  - Cholinergic drugs
  - Antiarrhythmic drugs: beta-blockers, verapamil, diltiazem, digoxin
  - CYP2D6, CYP3A4 inducer/inhibitor

## NMDA receptor antagonist

- Side effect: somnolence, constipation
- Do not prescribe if !
  - eGFR <30 → max dose 10 mg/day
  - Uncontrolled seizure




Drugs	Start dose	Available dose	Max dose/day
Donepezil	2.5-5 mg OD	5, 10, 23 mg	23 mg
Galantamine	8 mg OD	8, 16, 24 mg	24 mg
Rivastigmine	1.5 mg BID	1.5, 3, 4.5 mg	12 mg
Rivastigmine oral solution	1.5 mg BID	2 mg/mL (120 mL/bottle)	12 mg
Rivastigmine patch	4.6 mg/24 hr	4.6, 9.5, 13.3 mg	13.3 mg/24 hr
Memantine	5 mg HS (BID)	10 mg	20 mg
Memantine oral solution	5 mg HS (BID)	5 mg/ 1 pump =2 mg/mL (360 mL/bottle)	20 mg





# Rivastigmine patch





# BPSD

(Behavioral and Psychological Symptoms of Dementia)

# BPSD

**Aggression (physical or verbal)**

**Disinhibition:**

- Socially inappropriate behavior
- Sexually inappropriate behavior

**Irritability or lability**

**Motor disturbance (repetitive activities without purpose):**

- Wandering
- Rummaging

**Night-time behaviors (waking and getting up at night)**

**Depression or dysphoria**

**Anxiety:**

- Worrying
- Shadowing (following care giver)

**Apathy or indifference**

**Delusion**

**Hallucination**

**Agitation:**

- Easily upset
- Repeating questions
- Arguing or complaining
- Hoarding
- Pacing
- Inappropriate screaming, crying out, disruptive sounds
- Rejection of care (for example, bathing, dressing, grooming)
- Leaving home

- Non-pharmacologic management  
→ 1<sup>st</sup> line recommendation
- Pharmacologic management

# Factors Associated with BPSD

Patient	Caregiver	Environment
<ul style="list-style-type: none"><li>• Premorbid personality</li><li>• Psychiatric illness</li><li>• Acute medical problems</li><li>• Unmet needs</li></ul>	<ul style="list-style-type: none"><li>• Stress, burden, depression</li><li>• Lack of education about dementia</li><li>• Negative communication styles</li><li>• Coping abilities</li><li>• Mismatch of expectations and dementia severity</li></ul>	<ul style="list-style-type: none"><li>• Overstimulation</li><li>• Understimulation</li><li>• Safety issues</li><li>• Lack of activity and structure</li><li>• Lack of established routines</li></ul>

# BPSD Management: **A B C**

- **A ntecedents:** What are the triggers for the behavior(s)?
- **B ehavior:** Which behavior, or behaviors, are targets for intervention?
- **C onsequences:** What are the consequences of the behavior(s) for the patient and others?





# Targeting Management

**Patient**

**Caregiver**

**Environment**



# Functional Assessment Staging (FAST) tool

Stage	Stage Name	Characteristic
1	Normal Aging	No deficits whatsoever
2	Possible Mild Cognitive Impairment	Subjective functional deficit
3	Mild Cognitive Impairment	Objective functional deficit interferes with a person's most complex tasks
4	Mild Dementia	IADLs become affected, such as bill paying, cooking, cleaning, traveling
5	Moderate Dementia	Needs help selecting proper attire
6a	Moderately Severe Dementia	Needs help putting on clothes
6b	Moderately Severe Dementia	Needs help bathing
6c	Moderately Severe Dementia	Needs help toileting
6d	Moderately Severe Dementia	Urinary incontinence
6e	Moderately Severe Dementia	Fecal incontinence
7a	Severe Dementia	Speaks 5-6 words during day
7b	Severe Dementia	Speaks only 1 word clearly
7c	Severe Dementia	Can no longer walk
7d	Severe Dementia	Can no longer sit up
7e	Severe Dementia	Can no longer smile
7f	Severe Dementia	Can no longer hold up head

# Predicting mortality rate in nursing home residents with advanced dementia

<b>Patients who had</b>	<b>6 month mortality rate</b>
Pneumonia	46.7%
Febrile episode	44.5%
Eating problem	38.6%



Cause of death	Demented patients (%)	General population (%)
<b>Neoplasm</b>	<b>3.8</b>	<b>21.3</b>
<b>Circulatory system disease</b>	<b>37.4</b>	<b>47.9</b>
Ischaemic heart disease	23.1	22.0
Cerebrovascular disease	4.2	11.5
Pulmonary embolism	5.7	0.7
Other circulatory system disease	4.4	13.7
<b>Respiratory system disease</b>	<b>45.8</b>	<b>7.4</b>
Bronchopneumonia	38.4	2.8 <sup>a</sup>
Aspiration pneumonia and asphyxia	6.7	0.2
Other respiratory system disease	0.8	4.5
<b>Digestive system disease</b>	<b>4.2</b>	<b>3.2</b>
<b>Genitourinary system disease</b>	<b>2.3</b>	<b>1.7</b>
<b>Other cause</b>	<b>6.5</b>	<b>18.5</b>
Cachexia	2.1	b
Traumatic falls	0.6	b
Specified infection	0.4	b
(including tuberculosis)		
Unresolved	3.4	b

# Medication Appropriateness in Advance Dementia

- **Always appropriate:**

- Analgesics
- Antidiarrheals
- Antiemetics
- Laxatives
- Inhaled bronchodilators
- Anxiolytics
- Antiepileptics
- Expectorants
- Lubricating eye drops
- Pressure ulcer treatment

- **Never appropriate:**

- Acetylcholinesterase inhibitors
- Memantine
- Lipid modifying agents
- Antiplatelets excluding aspirin
- Hormone antagonists
- Cytotoxic chemotherapy
- Immunostimulators
- Leukotriene receptor antagonists